---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-023261"
form_type: "8-K"
ticker: "GRCE"
cik: "0001444192"
company_name: "Grace Therapeutics, Inc."
filed_at: "2025-06-23T23:59:59+00:00"
generated_at: "2026-05-18T23:31:15.893935+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Grace Therapeutics reports FY2025 net loss of $9.6M; NDA for GTx-104 on track for June 2025 submission

## Summary
- Net loss of $9.6M ($0.79 per share) vs $12.9M ($1.35) in FY2024, decrease driven by change in warrant liabilities.
- R&D expenses rose to $9.5M (FY2024: $4.7M) due to the STRIVE-ON Phase 3 trial; cash at $22.1M.
- NDA for GTx-104 for aSAH expected to be submitted to FDA by end of June 2025 following positive Type C meeting.
- Secured $15M upfront private placement (led by Nantahala Capital, ADAR1 Partners) with potential $15M from warrants.
- STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%).

## SEC filing metadata
- accession: 0001140361-25-023261
- form_type: 8-K
- ticker: GRCE
- cik: 0001444192
- company_name: Grace Therapeutics, Inc.
- filed_at: 2025-06-23T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/0001140361-25-023261-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1444192/000114036125023261/ef20050698_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-023261
- JSON: https://secwatch.observer/filing/0001140361-25-023261.json
- Plain text: https://secwatch.observer/filing/0001140361-25-023261.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.